Loading clinical trials...

A Fourteen-Week Placebo-Controlled Dose-Response Efficacy and Safety Study of NS 2330 in Early Parkinson's Disease Patients (Study for Proof of Concept in Early Parkinson's Disease of a Triple Reuptake Inhibitor, NS 2330 / SCEPTRE) | Clinical Trials | Clareo Health

COMPLETEDPHASE2

A Fourteen-Week Placebo-Controlled Dose-Response Efficacy and Safety Study of NS 2330 in Early Parkinson's Disease Patients (Study for Proof of Concept in Early Parkinson's Disease of a Triple Reuptake Inhibitor, NS 2330 / SCEPTRE)

A Fourteen-week Placebo-controlled Dose-response Efficacy and Safety Study of NS 2330 in Early Parkinson's Disease Patients (Study for Proof of Concept in Early Parkinson's Disease of a Triple Reuptake Inhibitor, NS 2330 / SCEPTRE)

NCT00148486•Boehringer Ingelheim

View on ClinicalTrials.gov

Summary

To demonstrate efficacy and dose-response of NS 2330 versus placebo in patients with early Parkinson's Disease in 14 weeks of treatment, and to investigate the safety and tolerability of NS 2330 in these patients.

Eligibility

Age

40 - 80 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Parkinson's disease for \<5 years, non-demented, no or \<6 months of levodopa and none during trial. Off levodopa, DA agonists, and psychotropics for 30 days before screening. Amantadine, anticholinergics allowed if at stable dosage. Hoehn \& Yahr stage I-III. Depression allowed, but no other chronic disease that is unstable or might interfere with ability to participate.

Locations (55)

Pivotal Reaserch Centers

Peoria, Arizona, United States

Boehringer Ingelheim Investigational Site

Tucson, Arizona, United States

PMDI

Fountain Valley, California, United States

Boehringer Ingelheim Investigational Site

Fresno, California, United States

Boehringer Ingelheim Investigational Site

Irvine, California, United States

Boehringer Ingelheim Investigational Site

Ocenside, California, United States

Boehringer Ingelheim Investigational Site

Oxnard, California, United States

West Los Angeles VA Medical Center

West Los Angeles, California, United States

Boehringer Ingelheim Investigational Site

Danbury, Connecticut, United States

UCONN Health Center

Farmington, Connecticut, United States

Key Dates

Start Date

June 1, 2003

Primary Completion Date

March 1, 2005

Last Updated

October 29, 2013

Enrollment

261

Estimated participants

Conditions

Parkinson Disease

Interventions

NS 2330

DRUG

Sponsors

Lead Sponsor

Boehringer Ingelheim

Related Studies

RECRUITINGPHASE1

[18F]F-DOPA Imaging in Patients With Autonomic Failure

NCT04246437

Autonomic FailurePure Autonomic Failure+3 more

Characterizing the Pathophysiological Role of the Pallido-thalamocortical Motor Pathway in Parkinson's Disease.

NCT06692920

Parkinson Disease

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 29, 2013Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions